WELTRUZA Trademark

Trademark Overview


On Wednesday, December 4, 2019, a trademark application was filed for WELTRUZA with the United States Patent and Trademark Office. The USPTO has given the WELTRUZA trademark a serial number of 88715004. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 29, 2023. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The WELTRUZA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
weltruza

General Information


Serial Number88715004
Word MarkWELTRUZA
Filing DateWednesday, December 4, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 29, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 3, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 10, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Tuesday, May 30, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 29, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, October 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 24, 2022SOU EXTENSION 5 GRANTED
Thursday, October 20, 2022SOU EXTENSION 5 FILED
Thursday, October 20, 2022TEAS EXTENSION RECEIVED
Saturday, April 23, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 21, 2022SOU EXTENSION 4 GRANTED
Thursday, April 21, 2022SOU EXTENSION 4 FILED
Thursday, April 21, 2022TEAS EXTENSION RECEIVED
Tuesday, December 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 13, 2021SOU EXTENSION 3 GRANTED
Thursday, October 28, 2021SOU EXTENSION 3 FILED
Thursday, December 9, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, October 29, 2021NOTICE OF REVIVAL - E-MAILED
Friday, October 29, 2021EXTENSION RECEIVED WITH TEAS PETITION
Friday, October 29, 2021PETITION TO REVIVE-GRANTED
Friday, October 29, 2021TEAS PETITION TO REVIVE RECEIVED
Thursday, October 28, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 28, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, October 28, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 28, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, April 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 14, 2021SOU EXTENSION 2 GRANTED
Wednesday, April 14, 2021SOU EXTENSION 2 FILED
Wednesday, April 14, 2021TEAS EXTENSION RECEIVED
Wednesday, October 28, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 26, 2020SOU EXTENSION 1 GRANTED
Monday, October 26, 2020SOU EXTENSION 1 FILED
Monday, October 26, 2020TEAS EXTENSION RECEIVED
Tuesday, April 28, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 3, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 3, 2020PUBLISHED FOR OPPOSITION
Wednesday, February 12, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 24, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 23, 2020ASSIGNED TO EXAMINER
Tuesday, December 10, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, December 7, 2019NEW APPLICATION ENTERED